| DC Field | Value | Language |
|---|
| dc.contributor.author | Solgalova, A. S. | - |
| dc.contributor.author | Soldatov, V. O. | - |
| dc.contributor.author | Pokrovskaya, T. G. | - |
| dc.contributor.author | Puchenkova, O. A. | - |
| dc.contributor.author | Zapesotskaya, S. Ya. | - |
| dc.contributor.author | Feitelson, A. V. | - |
| dc.contributor.author | Sernov, L. N. | - |
| dc.contributor.author | Provotorov, V. Ya. | - |
| dc.contributor.author | Pahlevanyan, V. G. | - |
| dc.date.accessioned | 2020-06-09T16:30:24Z | - |
| dc.date.available | 2020-06-09T16:30:24Z | - |
| dc.date.issued | 2019 | - |
| dc.identifier.citation | Betahistine: targeting on vascular wall aging / A.S. Solgalova, V.O. Soldatov, T.G. Pokrovskaya [et al.] // Journal of international pharmaceutical research. - 2019. - Vol.46, №4.-P. 286-290. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/31735 | - |
| dc.description.abstract | Betahistine are routine drug in neurological practice, which is used to correct vertigo. The clinical efficacy of this drug can be caused not only by neuro-, but also by endotheliotropic action. In this review, the main information on the potential mechanisms for the implementation of vasoprotection, including metabolic, NO-ergic, anti-inflammatory and other components of the action are discussed | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | betahistine | ru |
| dc.subject | endothelial dysfunction | ru |
| dc.subject | atherosclerosis | ru |
| dc.subject | histamine | ru |
| dc.subject | vertigo | ru |
| dc.title | Betahistine: targeting on vascular wall aging | ru |
| dc.type | Article | ru |
| Appears in Collections: | Статьи из периодических изданий и сборников (на иностранных языках) = Articles from periodicals and collections (in foreign languages)
|
